Oramed Ltd.
1 more in force is now held by another company
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
3
Ending by 2030
Feb 2029
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Nov 30, 2026The maintenance fee for Methods and Compositions for Oral Administration of Proteins (US 11,660,327) comes due Nov 30, 2026. Unpaid by Jun 1, 2027, it lapses early.
- 1 fee due Jan 16, 2027The maintenance fee for Methods and compositions for oral administration of exenatide (US 10,350,162) comes due Jan 16, 2027. Unpaid by Jul 16, 2027, it lapses early.
- 1 fee due Mar 3, 2027The maintenance fee for Methods and Compositions for Treating Diabetes (US 10,398,762) comes due Mar 3, 2027. Unpaid by Sep 3, 2027, it lapses early.
Recent changes
- 1 term has ended since Aug 16, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Showing 1 to 7 of 7
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,881,714 | Methods and Compositions for Oral Administration of Proteins In force · High confidence | In force | High confidence | |
| US 11,660,327 | Methods and Compositions for Oral Administration of Proteins In force · High confidence | In force | High confidence | |
| US 10,350,162 | Methods and compositions for oral administration of exenatide In force · From the USPTO record | In force | From the USPTO record | |
| US 10,342,764 | Protease Inhibitor-Containing Compositions, Compositions Comprising Same, and Methods for Producing and Using Same In force · High confidence | In force | High confidence | |
| US 10,933,022 | Protease Inhibitor-Containing Compositions, Compositions Comprising Same, and Methods for Producing and Using Same In force · Low confidence | In force | Low confidence | |
| US 10,398,762 | Methods and Compositions for Treating Diabetes In force · High confidence | In force | High confidence | |
| US 10,967,051 | Methods and compositions for treating NAFLD, hepatic steatosis, and sequelae thereof In force · From the USPTO record | In force | From the USPTO record |
Also on record, not counted in the 7: 1 patent in force now held by others · 2 lapsed for an unpaid fee · 7 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
2 pending · 5 abandoned · 6 no status recorded